PANTIN 250MG INJECTION

Indications

• Pain management
• Inflammation
• Chronic disease management
• Specific pain syndromes

Dosage

Children: Refer to the relevant clinical guidelines or the BNF for Children for specific dosing information as it can vary based on the child's age, weight, and the condition being treated.

Adults: Refer to the relevant clinical guidelines or prescriptions for specific dosing information as it can vary based on the condition being treated.

Mechanism of action

The specific mechanism of action for Added may involve modulation of neurotransmitter pathways, inhibition of pro-inflammatory mediators, or interaction with specific receptor sites in the body. These actions can lead to reduced pain perception and inflammation.

Pharmacodynamics

Added exhibits its pharmacodynamic effects primarily through alterations in the central nervous system and peripheral tissues. It can lead to decreased sensitivity to pain, reduced inflammatory responses, and altered physiological functions depending on the condition being treated.

Pharmacokinetics

The pharmacokinetics of Added includes absorption, distribution, metabolism, and excretion processes. After administration, it is absorbed into the bloodstream, reaching peak plasma concentrations at variable times. It is generally metabolized in the liver and excreted via the kidneys, but the specific half-life and metabolic pathways may vary based on formulation and patient factors.

Pregnancy

Data on the safety of added during pregnancy is limited. It is recommended to assess the risks and benefits before use.

Breast-feeding

Caution is advised when using added during breastfeeding due to unknown effects on the infant.

Storage

Store in a cool, dry place away from direct sunlight. Keep out of reach of children.

Indications

• Metabolic acidosis
• Acid-base imbalance
• Urinary alkalinization
• Treatment of certain poisonings
• Cardiac arrest in the context of metabolic acidosis

Dosage

Children: Refer to the BNF for Children for specific pediatric dosages, as they depend on the clinical condition

Adults: Refer to local guidelines and BNF for specific dosing recommendations as they may vary based on clinical condition and severity. General adult dosing for bicarbonate may range from 1 to 2 mEq/kg IV initially, followed by maintenance doses as needed.

Mechanism of action

Bicarbonate acts as a buffer that neutralizes excess acids in the body. It dissociates in solution to produce bicarbonate ions (HCO3-) which can react with hydrogen ions (H+) to form carbonic acid (H2CO3), subsequently leading to the production of carbon dioxide (CO2) and water (H2O). This process helps to raise the pH of the blood and other fluids, counteracting acidosis. Bicarbonate is involved in several metabolic pathways, including the urea cycle and various biosynthetic pathways.

Pharmacodynamics

Bicarbonate's primary pharmacodynamic effect is its ability to buffer hydrogen ions, thus increasing blood pH. This is essential in conditions such as metabolic acidosis, where the body accumulates excess acid. By raising blood pH, bicarbonate can help alleviate symptoms associated with acidemia, such as fatigue, confusion, and shortness of breath. Its effects can also influence the renal and respiratory systems to regulate acid-base homeostasis.

Pharmacokinetics

Bicarbonate is rapidly absorbed from the gastrointestinal tract. It is distributed throughout the body fluids, and its effects can be seen within minutes of administration. The kidneys play a significant role in bicarbonate homeostasis by reabsorbing bicarbonate from urine and excreting hydrogen ions. The elimination half-life can vary, depending on the patient's metabolic state and renal function.

Pregnancy

Use with caution. Consult with a healthcare provider before use.

Breast-feeding

Use with caution. Consult with a healthcare provider before use.

Storage

Store in a cool, dry place away from light.

Indications

• pH stabilization in laboratory experiments
• buffering during physiological studies
• preparation of samples for biochemical assays
• maintenance of pH in parenteral fluids

Dosage

Children: Refer to specific buffer formulations for detailed dosing guidance.

Adults: Refer to specific buffer formulations for detailed dosing guidance.

Mechanism of action

Buffers work by neutralizing added acids or bases through chemical reactions. For example, a buffer composed of acetic acid and sodium acetate can absorb excess hydrogen ions (from added acids) or donate hydrogen ions (to neutralize added bases), thus stabilizing the pH of the solution. This equilibrium is governed by the Henderson-Hasselbalch equation, which relates pH to the concentrations of the acidic and basic components of the buffer.

Pharmacodynamics

The pharmacodynamics of buffers involves their capacity to maintain pH levels within a target range, which is essential for various physiological processes. For instance, physiological buffers such as bicarbonate and phosphate play critical roles in maintaining the acid-base balance in the body, ensuring proper cellular function, enzyme activity, and metabolic processes.

Pharmacokinetics

The pharmacokinetics of buffer components depends on their specific chemical nature. Weak acids and bases used in buffers are typically absorbed and metabolized according to their molecular characteristics. For instance, bicarbonate can be reabsorbed in the kidneys and plays a significant role in systemic pH regulation. However, since buffer solutions are not typically absorbed in the same way as pharmaceutical drugs, their pharmacokinetic profiles are less relevant in a conventional sense.

Pregnancy

Buffering agents are generally considered safe during pregnancy; however, specific formulations should be evaluated for safety and efficacy.

Breast-feeding

Most buffering agents are considered safe during breastfeeding, but it is advisable to consult healthcare providers regarding specific formulations.

Storage

Store in a cool, dry place, away from direct sunlight and moisture. Follow specific storage instructions on the product label.

Indications

• Infection treatment with imipenem
• Prevention of renal toxicity associated with high doses of imipenem

Dosage

Children: Refer to the BNF for Children for appropriate pediatric dosing information.

Adults: Refer to the BNF for specific dosing guidelines as they may vary based on indication and patient factors.

Mechanism of action

Cilastatin inhibits the enzyme renal dehydropeptidase-I, which is responsible for the hydrolysis of imipenem in the renal tubules. This inhibition prevents the degradation of imipenem, allowing it to maintain its antimicrobial activity.

Pharmacodynamics

Cilastatin acts by blocking the action of renal dehydropeptidase, thereby protecting imipenem from being metabolized and increasing its renal excretion as unchanged drug. While cilastatin does not display any direct antibacterial activity, its role in preserving imipenem levels helps mitigate the risk of nephrotoxicity associated with high doses of imipenem.

Pharmacokinetics

The pharmacokinetics of cilastatin involves its administration alongside imipenem, with cilastatin enhancing the pharmacological profile of imipenem. Cilastatin is administered intravenously, and its half-life and metabolic pathways are closely tied to those of imipenem. The renal clearance of cilastatin is significant, and it plays a protective role against renal damage from imipenem.

Pregnancy

Cilastatin should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. There are no adequate and well-controlled studies in pregnant women.

Breast-feeding

Cilastatin is excreted in human milk. Caution should be exercised when administering to breastfeeding women.

Storage

Store at room temperature, away from light and moisture. Do not freeze.

Formulations

• Cilastatin sodium for injection

Indications

• Severe bacterial infections
• Intra-abdominal infections
• Pneumonia
• Urinary tract infections
• Skin and soft tissue infections
• Bone and joint infections
• Meningitis

Dosage

Children: Refer to the BNF for Children for specific dosing guidelines for paediatric patients, as doses vary based on age and weight.

Adults: The usual adult dose for imipenem ranges from 250 mg to 1 g administered intravenously every 6 to 8 hours, depending on the severity and type of infection.

Mechanism of action

Imipenem acts as an antimicrobial by inhibiting cell wall synthesis in various Gram-positive and Gram-negative bacteria. This mechanism is achieved through binding to penicillin-binding proteins (PBPs), particularly PBP-2, PBP-1a, and PBP-1b in E. coli and selected strains of Pseudomonas aeruginosa. The binding prevents the addition of peptidoglycan polymer to the bacterial cell wall, ultimately leading to cell lysis and death.

Pharmacodynamics

As a beta-lactam antibiotic, imipenem exhibits bactericidal properties by disrupting the synthesis of the bacterial cell wall. This activity is effective against a broad spectrum of pathogens, providing a crucial therapeutic option for serious infections, particularly those caused by resistant organisms.

Pharmacokinetics

Imipenem is typically administered intravenously due to its instability in acidic environments. It has a rapid distribution throughout the body, with peak plasma concentrations occurring shortly after administration. The drug is primarily excreted unchanged by the kidneys, and dose adjustments may be needed in patients with renal impairment. The half-life of imipenem is approximately 1 hour.

Contra-indications

• Hypersensitivity to imipenem or any of its components
• History of severe allergic reactions to other beta-lactam antibiotics

Adverse effects

• Nausea
• Vomiting
• Diarrhea
• Rash
• Seizures
• Superinfection
• Allergic reactions

Interactions

• Probenecid may increase plasma concentrations of imipenem
• Valproic acid may have decreased effectiveness when used with imipenem

Precautions

• Use with caution in patients with a history of seizures
• Assess renal function prior to use
• Monitor for signs of superinfection

Pregnancy

Use during pregnancy only if the potential benefit justifies the potential risk to the fetus, as there are no adequate and well-controlled studies in pregnant women.

Breast-feeding

Imipenem is excreted in breast milk, caution should be exercised when administering to nursing mothers.

Storage

Store in a cool, dry place, protected from light. Reconstituted solutions should be used promptly or stored in a refrigerator and discarded after 24 hours.

Formulations

• Powder for injection

Mechanism of action

Cilastatin is a renal dehydropeptidase-I inhibitor. Since the antibiotic, imipenem, is hydrolyzed by dehydropeptidase-I, which resides in the brush border of the renal tubule, cilastatin is administered with imipenem to block the metabolism of imipenem.

Pharmacodynamics

Cilastatin is a chemical compound which inhibits the human enzyme dehydropeptidase. Renal Dehydropeptidase degrades the antibiotic [imipenem]. Cilastatin is therefore combined intravenously with imipenem in order to protect it from dehydropeptidase and prolong its antibacterial effect. However, cilastatin in and of itself does not have any antibacterial activity. The increased renal excretion of unchanged imipenem appears to prevent proximal tubular necrosis associated with high doses of imipenem.

Mechanism of action

Imipenem acts as an antimicrobial through the inhibition of cell wall synthesis of various gram-positive and gram-negative bacteria. This inhibition of cell wall synthesis in gram-negative bateria is attained by binding to penicillin-binding proteins (PBPs). In E. coli and selected strains of P. aeruginosa, imipenem has shown to have the highest affinity to PBP-2, PBP-1a, and PBP-1b. This inhibition of PBPs prevents the bacterial cell from adding to the peptidoglycan polymer which forms the bacterial cell wall eventually leading to cell death.

Pharmacodynamics

Imipenem is a beta-lactam antibiotic belongings to the subgroup of carbapenems. Imipenem is active against aerobic and anaerobic Gram positive as well as Gram negative bacteria including <i>Pseudomonas aeruginosa</i> and the <i>Enterococcus</i>. It exerts a bactericidal effects by disrupting cell wall synthesis.